EDX Medical Group - Equity Fundraising raises £3.5 million

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended.  On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

February 16, 2026

EDX Medical Group plc

AQSE: EDX

("EDX Medical" or "the Company")

Equity Fundraising raises £3.5 million

CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular and infectious diseases, announces that the board of the Company has approved the issue of 24,999,999 new ordinary shares of 1p each in the Company (the "Subscription Shares") at a price of 14p per share (the "Fundraising") raising £3,500,000 for the Company.

Existing high net worth shareholders have subscribed to the Fundraising.  

The net proceeds of the Fundraising will support the acceleration of the Company's prostate cancer programme which involves the development and delivery of best-in-class diagnostic products and services.

Application has been made for the Subscription Shares to be admitted to trading on the AQSE Growth Market ("Admission") and the Subscription remains conditional on Admission.  It is expected that Admission will take place on Friday, February 20, 2026.

This latest fundraising follows the Company's announcement on October 20, 2025 that the Company secured up to £4 million funding for product development and commercial operations through a combination of the issue of 14,285,713 new ordinary shares of 1p each in the Company at a price of 14p per share to raise £2.0 million as well as the issue of a new convertible loan note (CLN) agreement for up to £2.0 million to Professor Sir Chris Evans, the Company's founder and Chief Scientific Officer.

Professor Sir Chris Evans, OBE, founder of EDX Medical, commented: "We are delighted that investors in the Company have once again reinforced their support for the work we are doing to provide game-changing diagnostic solutions for the early detection of prostate cancer. The need for innovation in this area has never been clearer as we have seen with the recent intense debate around screening for the disease.

"Men need better diagnostic solutions and we are making excellent progress in our cancer programmes particularly in prostate."

Dr Mike Hudson, Chief Executive Officer of EDX Medical, commented: "This investment is another vote of confidence in our strategy of developing and providing class-leading diagnostic solutions with immediate clinical benefits- improving outcomes for patients and delivering value for healthcare providers."

Total Voting Rights

In accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, the Company hereby announces that following the Fundraising, it will have   411,594,583 Ordinary Shares in issue, each share carrying the right to one vote. 

The above figure of 411,594,583 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

The directors of EDX Medical accept responsibility for the contents of this announcement.

 Contacts:

Notes for Editors:

About EDX Medical Group plc

EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.